#United States #New York #Class Action #Securities Fraud #Skye Bioscience

Upcoming Class Action Lawsuit Against Skye Bioscience, Inc.

On November 25, 2025, Levi & Korsinsky, LLP announced a significant development for investors of Skye Bioscience, Inc. (NASDAQ: SKYE). The firm has notified stakeholders about a pending class action lawsuit that addresses allegations of securities fraud, which occurred between November 4, 2024, and October 3, 2025.

Case Background

The lawsuit alleges that Skye Bioscience's lead product candidate, nimacimab, did not perform as effectively as the company had previously suggested. This false portrayal, according to the filed complaint, has led to an inflation of nimacimab's clinical and commercial prospects, which were misleading to investors and had a severe impact on their financial standing.

The ramifications for investors could be substantial, especially for those who have suffered losses directly tied to this perceived misinformation. If you believe you are one of the affected investors and wish to pursue any potential recovery, it is crucial to pay heed to the deadlines set in motion by this lawsuit.

Important Deadlines

Investors have until January 16, 2026, to request the court to appoint them as lead plaintiffs in this class action suit. Notably, participation in the case does not require one to be a lead plaintiff, allowing investors a chance to seek compensation regardless of their role in the lawsuit.

No Cost to Participate

One reassuring aspect for potential class members is the zero-cost guarantee for participating in this class action. Investors can gain compensation without bearing any out-of-pocket expenses or fees, alleviating some of the financial burdens that may discourage participation in such legal actions.

Why Choose Levi & Korsinsky?

The law firm Levi & Korsinsky has built an impressive reputation over the past two decades. Specializing in securities litigation, they have recovered hundreds of millions of dollars for aggrieved shareholders. Their team comprises over 70 skilled professionals dedicated to complex securities cases. The firm has consistently ranked among the top securities litigation firms in the United States, recognized in the ISS Securities Class Action Services' Top 50 Report for seven consecutive years.

Steps to Take

If you are a current or former investor of Skye Bioscience, it is vital to act swiftly. Interested parties can directly contact Joseph E. Levi, Esq. via email at [email protected] or by phone at (212) 363-7500. For those wishing to engage in the lawsuit, further information and the formal submission form are available through the link provided by Levi & Korsinsky.

Conclusion

Investors should stay informed and proactive regarding the ongoing developments of this class action lawsuit. The proceedings hold the potential for compensation for losses incurred due to the alleged securities fraud by Skye Bioscience, Inc. By participating, investors not only stand to regain some of their losses but also contribute to a collective response against corporate misconduct in the financial sector.